#### This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/26/2023 09:55 AM

# HOLD The Ramco Cements

# Market-share gains; leverage to remain high

### Cement > Result Update > November 9, 2023

The Ramco Cements reported healthy operational performance in Q2FY24, with EBITDA coming 21-22% higher than Street/our estimates. EBITDA increased 2x YoY/17% QoQ to Rs4bn, with EBITDA/t of Rs865. Volume growth of 39% YoY was robust at 4.6mt (Emkay est: 4.2mt). Overall cost/t declined 14% YoY/5% QoQ to Rs4,188, with the major part of savings owing to lower RM+P&F costs (down Rs201/t QoQ). Net debt further increased by Rs6bn QoQ to Rs50bn, as capex intensity saw a significant rise in H1FY24 (Rs12.5bn; also includes the land-acquisition deal from Prism Johnson). Adjusting for the higher capex, we expect net debt to broadly track a similar range till FY25. Building-in the Q2 beat and recent price-hike, we raise FY24E-26E EBITDA by 2% and revise Sep-24E TP to Rs990/sh, based on 13x EV/E (earlier 12x); retain HOLD.

The Ramco Cements:	Financial S	Snapshot (O	Consolidat	ed)	
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	60,037	81,573	93,779	1,01,487	1,11,743
EBITDA	12,901	11,856	17,281	20,517	23,081
Adj. PAT	8,815	3,145	5,066	7,372	9,567
Adj. EPS (Rs)	37.3	13.3	21.4	31.2	40.5
EBITDA margin (%)	21.5	14.5	18.4	20.2	20.7
EBITDA growth (%)	(17.2)	(8.1)	45.8	18.7	12.5
Adj. EPS growth (%)	12.3	(64.3)	61.1	45.5	29.8
RoE (%)	14.3	4.7	7.1	9.6	11.4
RoIC (%)	13.3	5.6	8.0	9.4	10.5
P/E (x)	27.4	76.8	47.7	32.8	25.2
EV/EBITDA (x)	21.7	24.0	16.8	14.0	12.1
P/B (x)	3.6	3.5	3.3	3.0	2.7
FCFF yield (%)	(2.4)	(1.2)	(0.5)	2.9	4.3

Source: Company, Emkay Research

### Result Summary

Ramco registered healthy volume growth of 39% YoY to 4.6mt, as the company continued to gain market share. Blended realization declined 6% YoY/3% QoQ to Rs5,053, owing to weak prices in TN and likely volume push. However, the impact of the same was negated by a decline in cost/t by 13% YoY/5% QoQ to Rs4,188. Besides the decline in fuel cost (Rs1.75/kcal vs. Rs2.03Kcal in Q1FY24), sharp increase in share of green power (up 900bps QoQ to 38%), and captive usage of wind energy resulted in RM+P&F cost reducing by Rs201/t QoQ in Q2FY24. The ensuing EBITDA/t grew 56% YoY/ 9% QoQ to Rs865 (Emkay: Rs780). Company acquired limestone mines in AP and Karnataka for augmenting its limestone reserves, post which capital outflow significantly rose to Rs9.4bn in Q2FY24. Consolidated FCF generation stood at a negative Rs5.5bn, post working-capital release of Rs502mn and capex spend of Rs12bn in H1FY24.

What we like: Industry-leading volume growth and beat on profitability

What we do not like: Increase in net debt

**Key takeaways from the result:** i) Management mentioned that the Kurnool line-2 (~2.5mt) will remain its priority and which it can commission in 12-15 months post capex announcement of <USD40/t. ii) Company has guided for capex of Rs16bn in FY24, which implies capex of Rs3-3.5bn in H2FY24. iii) The 0.9mt GU in Odisha is expected to be commissioned in Jan-24. iv) Net debt stands at Rs49.7bn, as of Sep-23; the management expects this to be the net-debt peak. v) Price-hikes in the South have been absorbed in Oct-23 and broadly sustained. vi) The management has guided for volume in H2FY24 to be similar to that recorded in H1FY24 (~9mt), implying 8% YoY growth in H2FY24. vii) Expects share of green power to improve 40%/45% in FY24/FY25, respectively. viii) P&F cost/t is likely to be similar on QoQ basis in Q3, as lower wind power benefit will be offset by the higher WHRS usage. ix) In Kolimigundala, the 3MW WHRS was commissioned in Aug-23. TPP of 18MW will be commissioned in Dec-23, and railway siding in Jun-24. Two units of dry mortar plants, in AP and Odisha, will be commissioned during Dec-23.



#### **TARGET PRICE (Rs): 990**

Target Price – 12M	Sep-24
Change in TP (%)	12.5
Current Reco.	HOLD
Previous Reco.	HOLD
Upside/(Downside) (%)	(3.1)
CMP (09-Nov-23) (Rs)	1,022.0
Stock Data	Ticker
52-week High (Rs)	1,040
52-week Low (Rs)	634
Shares outstanding (mn)	236.3
Market-cap (Rs bn)	241
Market-cap (USD mn)	2,899
Net-debt, FY24E (Rs mn)	49,659
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	450.1
ADTV-3M (USD mn)	5.4
Free float (%)	-
Nifty-50	19,395
INR/USD	83.3
Shareholding, Sep-23	
Promoters (%)	42.1
FPIs/MFs (%)	7.9/33.4

Price Performance									
(%)	1M	3M	12M						
Absolute	7.6	18.2	45.1						
Rel. to Nifty	8.3	19.7	35.8						



#### Dharmesh Shah

dharmesh.shah@emkayglobal.com +91 22 6612 1255

Cheragh Sidhwa cheragh.sidhwa@emkayglobal.com +91 22 6612 1219

# **Quarterly Analysis**

# Exhibit 1: Actual vs. Estimates (Q2FY24)

(Rs mn)	Actual	Esti	mates	Varia	tion (%)	Comment
(KS IIII)	Actual	Emkay	Consensus	Emkay	Consensus	
Net sales	23,293	21,637	21,169	7.7	10.0	
EBITDA	3,986	3,277	3,285	21.6	21.3	Comprehensive beat on EBITDA owing to lower input prices and higher volumes
PAT	1,013	662	801	53.1	26.5	
Volumes (mt)	4.6	4.2		9.7		
Cement realization (Rs/ton)	5,053	5,147		(1.8)		
EBITDA (Rs/ton)	865	780		10.9		

Source: Bloomberg, Emkay Research

# Exhibit 2: Quarterly financial highlights

(Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)	H1FY23	H1FY24	YoY (%)
Revenue	17,844	20,088	25,697	22,411	23,293	30.5	3.9	35,569	45,704	28.5
Expenditure	16,006	17,241	21,568	18,996	19,307	20.6	1.6	30,724	38,303	24.7
Total RM	2,698	2,781	5,310	3,268	4,419	63.8	35.2	5,339	7,687	44.0
Power & Fuel	6,664	7,023	7,686	7,559	6,262	(6.0)	(17.1)	11,908	13,821	16.1
Freight	3,481	3,958	4,994	4,577	4,724	35.7	3.2	7,078	9,301	31.4
Staff cost	1,121	1,128	1,131	1,266	1,385	23.5	9.4	2,203	2,650	20.3
Other expenditure	2,042	2,352	2,448	2,327	2,517	23.2	8.2	4,195	4,844	15.5
EBITDA	1,838	2,846	4,128	3,415	3,986	116.9	16.7	4,845	7,401	52.8
Depreciation	1,216	1,359	1,406	1,479	1,574	29.5	6.4	2,280	3,053	33.9
EBIT	622	1,488	2,723	1,936	2,412	287.6	24.6	2,565	4,348	69.5
Other Income	88	93	116	79	135	52.5	70.8	157	214	35.8
Interest	551	608	772	934	1,165	111.7	24.8	1,025	2,099	104.7
РВТ	160	972	2,067	1,081	1,382	762.4	27.8	1,697	2,462	45.1
Total Tax	46	299	543	292	369	710.1	26.4	460	660	43.6
Adjusted PAT	115	674	1,524	789	1,013	783.2	28.4	1,237	1,802	45.6
PAT after MI	115	674	1,524	789	1,013	783.2	28.4	1,237	1,802	45.6
Extra ordinary items	-	-	-	-	-			-	-	
Reported PAT	115	674	1,524	789	1,013	783.2	28.4	1,237	1,802	45.6
Adjusted EPS (Rs)	0.5	2.9	6.5	3.3	4.3	783.2	28.4	5.2	7.6	45.6

(%)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (bps)	QoQ (bps)	H1FY23	H1FY24	YoY (bps)
EBITDA	10.3	14.2	16.1	15.2	17.1	66.1	12.3	13.6	16.2	257
EBIT	3.5	7.4	10.6	8.6	10.4	196.9	19.9	7.2	9.5	230
EBT	0.9	4.8	8.0	4.8	5.9	560.7	23.0	4.8	5.4	62
PAT	0.6	3.4	5.9	3.5	4.3	576.6	23.5	3.5	3.9	46
Effective Tax rate	28.4	30.7	26.3	27.0	26.7			27.1	26.8	

Source: Company, Emkay Research

# Exhibit 3: Quarterly analysis on a per-ton basis

(Rs/ton)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)	H1FY23	H1FY24	YoY (%)
Total volumes (mt)	3.3	3.6	4.7	4.3	4.6	39.3	7.2	6.7	8.9	34.0
Blended Realization	5,377	5,577	5,448	5,198	5,043	(6.2)	(3.0)	5,335	5,118	(4.1)
Raw Material cost	815	779	1,130	760	959	17.6	26.1	803	863	7.5
Power & Fuel cost	2,013	1,966	1,635	1,758	1,358	(32.5)	(22.7)	1,791	1,551	(13.4)
Freight cost	1,052	1,108	1,063	1,064	1,025	(2.6)	(3.7)	1,064	1,044	(1.9)
Staff cost	339	316	241	294	300	(11.3)	2.1	331	297	(10.2)
Other expenditure	617	658	521	541	546	(11.5)	0.9	631	544	(13.8)
Operating cost	4,835	4,827	4,589	4,418	4,188	(13.4)	(5.2)	4,620	4,299	(7.0)
Blended EBITDA	555	797	878	794	865	55.7	8.9	729	831	14.0

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 11/26/2023.09:55 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 4: We broadly maintain our EBITDA for FY24-26E

			FY24E			FY25E	FY26E			
(Rs mn)	Old	New	Chg. (%)	Old	New	Chg. (%)	Old	New	Chg. (%)	
Revenue	91,902	93,779	2.0	99,210	1,01,487	2.3	1,09,492	1,11,743	2.1	
EBITDA	16,902	17,281	2.2	20,119	20,517	2.0	22,731	23,081	1.5	
PAT	5,285	5,066	(4.1)	7,843	7,372	(6.0)	10,125	9,567	(5.5)	

Source: Emkay Research

Exhibit 5: We maintain HOLD on Ramco, with TP of Rs990/share, based on S	Sep-25E EV/E of 13x
EV/E valuation	
Sep-25E EBITDA (Rs bn)	22
EV/E (x)	13
Enterprise Value (Rs bn)	284
Net debt (Sep-24E; Rs bn)	50
Equity value (Rs bn)	234
No. of shares (mn)	236
Sep-24E Target Price (Rs/share)	990

Source: Emkay Research

## **Exhibit 6: Annual Analysis**

<b>v</b>	EV/10	574.0	EVOO	EVOI	5200	EVOO	52045	EVOEE	EVACE	CAGR	. (%)
Key Assumptions	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E	FY18-23	FY23-26E
Capacity (mt)	16.7	16.7	18.8	19.4	19.4	22.0	23.0	23.0	26.0	5.7	5.7
Volumes (mt)	9.3	11.1	11.2	10.0	11.0	14.8	18.0	19.1	20.6	9.7	8.8
Utilization (%)	56	67	60	51	57	67	78	83	79		
Blended Realization (Rs/ton)	4,728	4,619	4,788	5,278	5,392	5,465	5,197	5,306	5,410	2.9	(0.3)
EBITDA/ton (Rs)	1,181	959	1,024	1,560	1,168	800	960	1,075	1,120	(7.5)	10.3
P&L (Rs bn)											
Revenue	44	52	54	53	60	82	94	101	112	13.0	11.1
EBITDA	11	11	11	16	13	12	17	21	23	1.5	20.1
Adj. Net Profit	6	5	6	8	9	3	5	7	10	(10.6)	32.8
Balance Sheet (Rs bn)											
Equity	41	45	50	57	66	69	73	80	88		
Net Debt	10	15	29	30	38	44	50	46	38		
Net Debt:EBITDA (x)	0.9	1.4	2.6	1.9	2.9	3.7	2.9	2.2	1.7		
Net Debt:Equity (x)	0.2	0.3	0.6	0.5	0.6	0.6	0.7	0.6	0.4		
Cash Flow (Rs bn)											
OCF before WC change	9	9	10	13	10	10	11	14	16		
Change in WC	2	(1)	(3)	5	(0)	3	(1)	(0)	(0)		
Capex	(5)	(12)	(19)	(18)	(18)	(18)	(16)	(9)	(7)		
FCF	6	(4)	(12)	1	(8)	(5)	(6)	4	9		
Return ratios (%)											
RoE	14.0	12.3	12.7	15.0	14.3	4.7	7.1	9.6	11.4		
RoCE	9.9	8.7	8.2	9.1	9.4	4.1	6.5	7.9	9.0		
RoIC	11.0	10.4	10.8	12.4	13.7	5.9	8.3	9.6	10.8		
Valuations (x)											
PER						76.8	47.7	32.8	25.2		
EV/EBITDA						23.7	16.6	14.3	12.5		
EV/ton (USD)						158	154	153	131		

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 11/26/2023.09:55 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


# Exhibit 7: Annual analysis on a per-ton basis

(Rs/ton)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Blended realization	4,728	4,619	4,788	5,278	5,392	5,465	5,197	5,306	5,410
YoY (%)	(0.0)	(2.3)	3.7	10.2	2.1	1.4	(4.9)	2.1	2.0
Raw material costs	806	761	780	867	806	906	870	884	903
Power & fuel costs	783	950	938	796	1,257	1,796	1,473	1,434	1,453
Freight costs	997	1,068	1,016	1,028	1,099	1,081	1,051	1,060	1,070
Staff costs	327	304	340	420	394	326	301	309	312
Other expenses	657	599	713	630	711	595	553	555	563
Operating Costs	3,570	3,682	3,786	3,741	4,266	4,704	4,248	4,242	4,301
YoY (%)	7.3	3.1	2.8	(1.2)	14.0	10.3	(9.7)	(0.1)	1.4
Other operating income	23	22	22	23	43	38	11	11	11
Blended EBITDA	1,181	959	1,024	1,560	1,168	800	960	1,075	1,120
YoY (%)	(17.1)	(18.8)	6.8	52.4	(25.2)	(31.5)	20.0	12.0	4.2

Source: Company, Emkay Research



Exhibit 9: One-year forward EV/EBITDA



Source: Bloomberg, Emkay Research

Source: Bloomberg, Emkay Research

# **The Ramco Cements: Consolidated Financials and Valuations**

Profit and Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	60,037	81,573	93,779	1,01,487	1,11,743
Revenue growth (%)	13.5	35.9	15.0	8.2	10.1
EBITDA	12,901	11,856	17,281	20,517	23,081
EBITDA growth (%)	(17.2)	(8.1)	45.8	18.7	12.5
Depreciation & Amortization	4,022	5,060	6,015	6,205	6,518
EBIT	8,878	6,796	11,266	14,312	16,563
EBIT growth (%)	(26.1)	(23.5)	65.8	27.0	15.7
Other operating income	470	569	199	209	219
Other income	280	329	362	366	366
Financial expense	1,124	2,405	4,411	4,345	3,629
РВТ	8,034	4,720	7,217	10,333	13,300
Extraordinary items	0	0	0	0	0
Taxes	(894)	1,300	1,876	2,687	3,458
Minority interest	5	2	2	2	2
Income from JV/Associates	(109)	(272)	(272)	(272)	(272)
Reported PAT	8,815	3,145	5,066	7,372	9,567
PAT growth (%)	12.5	(64.3)	61.1	45.5	29.8
Adjusted PAT	8,815	3,145	5,066	7,372	9,567
Diluted EPS (Rs)	37.3	13.3	21.4	31.2	40.5
Diluted EPS growth (%)	12.3	(64.3)	61.1	45.5	29.8
DPS (Rs)	3.0	2.0	2.1	3.1	4.0
Dividend payout (%)	8.0	15.0	10.0	10.0	10.0
EBITDA margin (%)	21.5	14.5	18.4	20.2	20.7
EBIT margin (%)	14.8	8.3	12.0	14.1	14.8
Effective tax rate (%)	(11.1)	27.5	26.0	26.0	26.0
NOPLAT (pre-IndAS)	9,866	4,924	8,337	10,591	12,257
Shares outstanding (mn)	236.3	236.3	236.3	236.3	236.3

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	236	236	236	236	236
Reserves & Surplus	65,950	68,374	72,934	79,568	88,179
Net worth	66,186	68,611	73,170	79,805	88,415
Minority interests	68	70	70	70	70
Deferred tax liability (net)	8,212	9,250	9,250	9,250	9,250
Total debt	39,645	45,213	50,213	46,903	39,055
Total liabilities & equity	1,14,111	1,23,144	1,32,704	1,36,028	1,36,790
Net tangible fixed assets	75,953	1,00,383	1,11,955	1,16,663	1,18,820
Net intangible assets	670	670	670	670	670
Net ROU assets	219	209	219	219	219
Capital WIP	29,922	19,269	17,342	15,608	14,047
Goodwill	0	0	0	0	0
Investments [JV/Associates]	4,275	4,016	4,519	4,519	4,519
Cash & equivalents	1,785	1,703	554	756	667
Current assets (ex-cash)	18,751	19,675	23,787	24,227	27,349
Current Liab. & Prov.	17,464	22,779	26,342	26,634	29,501
NWC (ex-cash)	1,287	(3,105)	(2,555)	(2,407)	(2,152)
Total assets	1,14,111	1,23,144	1,32,704	1,36,028	1,36,790
Net debt	37,860	43,510	49,659	46,147	38,387
Capital employed	1,14,111	1,23,144	1,32,704	1,36,028	1,36,790
Invested capital	78,130	98,156	1,10,288	1,15,145	1,17,556
BVPS (Rs)	280.1	290.4	309.6	337.7	374.2
Net Debt/Equity (x)	0.6	0.6	0.7	0.6	0.4
Net Debt/EBITDA (x)	2.9	3.7	2.9	2.2	1.7
Interest coverage (x)	8.1	3.0	2.6	3.4	4.7
RoCE (%)	8.6	6.0	9.1	10.9	12.4

Source: Company, Emkay Research

Cash Flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
РВТ	8,034	4,720	7,217	10,333	13,300
Others (non-cash items)	(82)	(253)	0	0	0
Taxes paid	(1,587)	(327)	(1,876)	(2,687)	(3,458)
Change in NWC	(163)	2,510	(550)	(148)	(255)
Operating cash flow	11,349	14,114	14,580	17,408	19,094
Capital expenditure	(18,106)	(17,635)	(16,174)	(9,179)	(7,113)
Acquisition of business	(226)	523	0	0	0
Interest & dividend income	78	74	362	366	366
Investing cash flow	(18,157)	(16,940)	(15,812)	(8,814)	(6,748)
Equity raised/(repaid)	23	0	0	0	0
Debt raised/(repaid)	8,257	5,790	5,000	(3,310)	(7,848)
Payment of lease liabilities	1	0	0	0	0
Interest paid	(1,126)	(2,335)	(4,411)	(4,345)	(3,629)
Dividend paid (incl tax)	0	(710)	(507)	(737)	(957)
Others	0	0	0	0	0
Financing cash flow	7,154	2,745	82	(8,392)	(12,434)
Net chg in Cash	346	(81)	(1,149)	202	(88)
OCF	11,349	14,114	14,580	17,408	19,094
Adj. OCF (w/o NWC chg.)	11,512	11,604	15,130	17,556	19,348
FCFF	(6,757)	(3,521)	(1,594)	8,228	11,980
FCFE	1,501	2,269	3,406	4,918	4,132
OCF/EBITDA (%)	88.0	119.0	84.4	84.8	82.7
FCFE/PAT (%)	17.0	72.1	67.2	66.7	43.2
FCFF/NOPLAT (%)	(68.5)	(71.5)	(19.1)	77.7	97.7

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and Key R	atios				
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	27.4	76.8	47.7	32.8	25.2
P/CE(x)	18.8	29.4	21.8	17.8	15.0
P/B (x)	3.6	3.5	3.3	3.0	2.7
EV/Sales (x)	4.7	3.5	3.1	2.8	2.5
EV/EBITDA (x)	21.7	24.0	16.8	14.0	12.1
EV/EBIT(x)	31.5	41.9	25.8	20.1	16.9
EV/IC (x)	3.6	2.9	2.6	2.5	2.4
FCFF yield (%)	(2.4)	(1.2)	(0.5)	2.9	4.3
FCFE yield (%)	0.5	0.8	1.2	1.7	1.5
Dividend yield (%)	0.3	0.2	0.2	0.3	0.4
DuPont-RoE split					
Net profit margin (%)	14.7	3.9	5.4	7.3	8.6
Total asset turnover (x)	0.6	0.7	0.7	0.8	0.8
Assets/Equity (x)	1.7	1.8	1.8	1.8	1.6
RoE (%)	14.3	4.7	7.1	9.6	11.4
DuPont-RoIC					
NOPLAT margin (%)	16.4	6.0	8.9	10.4	11.0
IC turnover (x)	0.8	0.9	0.9	0.9	1.0
RoIC (%)	13.3	5.6	8.0	9.4	10.5
Operating metrics					
Core NWC days	7.8	(13.9)	(9.9)	(8.7)	(7.0)
Total NWC days	7.8	(13.9)	(9.9)	(8.7)	(7.0)
Fixed asset turnover	0.5	0.6	0.6	0.6	0.6
Opex-to-revenue (%)	63.7	69.0	64.9	63.1	62.7

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 11/26/2023 09:55 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
28-Sep-23	909	880	Hold	Dharmesh Shah
18-Sep-23	886	880	Hold	Dharmesh Shah
07-Aug-23	874	880	Hold	Dharmesh Shah
03-Jun-23	915	880	Hold	Dharmesh Shah
19-May-23	844	880	Hold	Dharmesh Shah
04-May-23	754	715	Hold	Dharmesh Shah
02-Mar-23	726	715	Hold	Dharmesh Shah
07-Feb-23	701	715	Hold	Dharmesh Shah
05-Feb-23	683	670	Hold	Dharmesh Shah
29-Dec-22	700	670	Hold	Dharmesh Shah
05-Dec-22	692	670	Hold	Dharmesh Shah
09-Nov-22	704	670	Hold	Dharmesh Shah
05-Nov-22	727	710	Hold	Dharmesh Shah
04-Oct-22	757	710	Hold	Dharmesh Shah
04-Sep-22	748	710	Hold	Dharmesh Shah
01-Aug-22	752	710	Hold	Dharmesh Shah
04-Jul-22	645	650	Hold	Dharmesh Shah
28-Jun-22	628	650	Hold	Dharmesh Shah
23-May-22	680	770	Hold	Dharmesh Shah
16-Mar-22	750	800	Hold	Dharmesh Shah
25-Jan-22	861	1,050	Buy	Dharmesh Shah
31-Dec-21	1,004	1,200	Buy	Dharmesh Shah
02-Dec-21	951	1,200	Buy	Dharmesh Shah
26-Oct-21	1,015	1,200	Buy	Dharmesh Shah
05-Sep-21	1,047	1,175	Hold	Dharmesh Shah
28-Jul-21	1,041	1,175	Hold	Dharmesh Shah
06-Jun-21	987	1,020	Hold	Dharmesh Shah
25-May-21	946	1,020	Hold	Dharmesh Shah
28-Apr-21	979	1,020	Hold	Dharmesh Shah

Source: Company, Emkay Research

### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 11/26/2023.09:55 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay@whitemarguesolutions com use and downloaded at 11/26/2023.09:55 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for gualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of November 9, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of November 9, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the November 9, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for 7 investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

# Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 11/26/2023 09:55 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.